Study on new migraine drugs in real life
Part of Brain & nervous system, Pain clinical trials.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with migraine by a doctor
- You are prescribed one of these migraine drugs: erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant, or rimegepant
- You are willing to sign a consent form to participate
- You do not have a different type of headache disorder (like tension headache or cluster headache)
- You do not have a severe active psychiatric condition or thinking/memory problems that would prevent you from understanding the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is building a database to learn more about migraine drugs. It may help researchers find better treatments for people with episodic or chronic migraine.
This study looks at blood samples from people with migraine to find proteins and other markers that might explain why migraines happen. The goal is to better understand migraine, which could help find better treatments in the future.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
This study tracks the health of pregnant women with migraine who take Aimovig. It helps doctors understand if the medicine is safe to use during pregnancy.
This study tests a CGRP-blocking antibody to see how it affects migraine symptoms and the body’s automatic (involuntary) nerve functions. It may help people with migraine who have already tried several preventive medicines.
This study tests how well a new acute migraine medicine, zavegepant, works and is tolerated in people who are already taking a CGRP-targeting preventive medication. It may help you find an effective treatment when you get a migraine attack.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.